These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33476436)

  • 1. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia.
    Jonas BA; Fisch SC; Rosenberg AS; Hoeg RT; Tuscano JM; Abedi M
    Am J Hematol; 2021 Apr; 96(4):E114-E117. PubMed ID: 33476436
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
    Rausch CR; Jabbour EJ; Kantarjian HM; Kadia TM
    Cancer; 2020 Mar; 126(6):1152-1160. PubMed ID: 31794095
    [No Abstract]   [Full Text] [Related]  

  • 3. Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.
    Cassaday RD; Stevenson PA; Wood BL; Becker PS; Hendrie PC; Sandmaier BM; Radich JL; Shustov AR
    Am J Hematol; 2018 Aug; 93(4):546-552. PubMed ID: 29318644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
    Romaguera JE; Wang M; Feng L; Fayad LE; Hagemeister F; McLaughlin P; Rodriguez MA; Fanale M; Orlowski R; Kwak LW; Neelapu S; Oki Y; Pro B; Younes A; Samaniego F; Fowler N; Hartig K; Valentinetti M; Smith J; Ford P; Naig A; Medeiros LJ; Kantarjian HM; Goy A
    Cancer; 2018 Jun; 124(12):2561-2569. PubMed ID: 29723393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience.
    Jain P; Kantarjian H; Ravandi F; Thomas D; O'Brien S; Kadia T; Burger J; Borthakur G; Daver N; Jabbour E; Konopleva M; Cortes J; Pemmaraju N; Kelly MA; Cardenas-Turanzas M; Garris R; Faderl S
    Leukemia; 2014 Apr; 28(4):973-5. PubMed ID: 24157581
    [No Abstract]   [Full Text] [Related]  

  • 6. Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
    Schrappe M; Bleckmann K; Zimmermann M; Biondi A; Möricke A; Locatelli F; Cario G; Rizzari C; Attarbaschi A; Valsecchi MG; Bartram CR; Barisone E; Niggli F; Niemeyer C; Testi AM; Mann G; Ziino O; Schäfer B; Panzer-Grümayer R; Beier R; Parasole R; Göhring G; Ludwig WD; Casale F; Schlegel PG; Basso G; Conter V
    J Clin Oncol; 2018 Jan; 36(3):244-253. PubMed ID: 29148893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy.
    Sawaki A; Miyazaki K; Yamaguchi M; Takeuchi T; Kobayashi K; Imai H; Tawara I; Ono R; Nosaka T; Katayama N
    Int J Hematol; 2020 May; 111(5):686-691. PubMed ID: 31993939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acute lymphoblastic leukemia: experience in adult patients treated with hyperCVAD and 0195 Protocol, at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Cohort 2003-2007].
    Arteaga-Ortiz L; Buitrón-Santiago N; Rosas-López A; Rosas-Arzate G; Armengolt-Jiménez A; Aguayo A; López-Karpovitch X; Crespo-Solís E
    Rev Invest Clin; 2008; 60(6):459-69. PubMed ID: 19378832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebellar toxicity following hyperCVAD regimen for acute lymphoblastic leukaemia.
    Koh LP; Lim LC
    Br J Haematol; 1999 Mar; 104(3):644-5. PubMed ID: 10086812
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytarabine induced noncardiogenic pulmonary edema in a case of acute lymphoblastic leukemia.
    Yegin ZA; Aki S; Sucak G; Yagci M
    Int J Lab Hematol; 2007 Dec; 29(6):482-3. PubMed ID: 17988309
    [No Abstract]   [Full Text] [Related]  

  • 12. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S
    Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hyper-CVAD regimen in adult acute lymphocytic leukemia.
    Garcia-Manero G; Kantarjian HM
    Hematol Oncol Clin North Am; 2000 Dec; 14(6):1381-96, x-xi. PubMed ID: 11147229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive paresthesia and weakness after intrathecal chemotherapy.
    Marshall R; Gupta ND; Palacios E; Neitzschman HR
    J La State Med Soc; 2008; 160(2):92-4. PubMed ID: 18681351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian HM; O'Brien S; Smith TL; Cortes J; Giles FJ; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha CS; Keating MJ; Murphy S; Freireich EJ
    J Clin Oncol; 2000 Feb; 18(3):547-61. PubMed ID: 10653870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.
    Chen S; Wu D; Sun A; Qiu H; Jin Z; Tang X; Miao M; Fu Z; Ma X; Han Y; Hu X
    Am J Hematol; 2007 Oct; 82(10):942. PubMed ID: 17617780
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia.
    Alfaraj WA; Cachia D; Tummala S; Thomas SK; Manasanch EE
    Ann Hematol; 2016 Jan; 95(2):347-8. PubMed ID: 26432713
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.
    Merli F; Luminari S; Ilariucci F; Petrini M; Visco C; Ambrosetti A; Stelitano C; Caracciolo F; Di Renzo N; Angrilli F; Carella AM; Capodanno I; Barbolini E; Galimberti S; Federico M
    Br J Haematol; 2012 Feb; 156(3):346-53. PubMed ID: 22145911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.